A Small Molecule Based Bispecific Antigenic Immunotherapy for the treatment of Dengue

Respi-DART 2024
Written By Conrrad Nicholls

Conrrad Nicholls

Eradivir Inc

Sign up to read this post
Join Now
Previous

Novel Ligand-Targeted Immunotherapy for the treatment of Human Respiratory Syncytial Virus
Next

Virologic Response and Safety After Oral Administration of PF-07817883, a Novel SARS-CoV-2 Mpro inhibitor, in Nonhospitalized Adults With Symptomatic COVID-19